Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 171 participants.
Also called NCT07093476
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 171 participants
- Sponsor
- Registry
-
NCT07093476
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07093476. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
- Condition
- T2DM
- Condition
- Diabete Type 2
- Condition
- DM
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- empagliflozin
- Lead sponsor
- Celltrion
Record details
- Record id
cardio:ct-nct07093476- Content hash
56b80a42fccf7e33e63a8ef82e8ce288dc53512dc713ade6bb33c1b4ac5d271b